In January, there were suspensions of the first doses and shortages to inoculate the second ones due to production problems at Pfizer and Moderna’s delays in the delivery of vials. In March, the cases of thrombi in those vaccinated with AstraZeneca that severely eroded confidence in this vaccine and forced to reconsider the age groups it was aimed at. And in April, new cases of thrombi in young and middle-aged women vaccinated with Janssen in the United States, something that led to Johnson & Johnson paralyzing the administration of doses of its own vaccine.
The vaccination race against COVID-19, one of the great events of our lives, is presenting some complications, and the latter is especially delicate: Janssen’s is a key vaccine to reach the deadlines set by the Government of Spain, which set for the last week of August the figure of 33 million vaccinated: 70% of the Spanish population, and therefore, the longed-for group immunity. However, the vaccine that does not need deep freezers or a second dose is on a pause from which it will be necessary to see when it comes out, and in what way. Any day that passes without recourse to its doses will further jeopardize the achievement of the summer goal.
Read more